Virological and serological characterization of critically ill patients with COVID-19 in the UK: interactions of viral load, antibody status and B.1.1.7 variant infection
<br><strong>Background<br></strong> Convalescent plasma containing neutralizing antibody to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is under investigation for coronavirus disease 2019 (COVID-19) treatment. We report diverse virological characteristics of...
Huvudupphovsmän: | Ratcliff, J, Nguyen, D, Fish, M, Rynne, J, Jennings, A, Williams, S, Al-Beidh, F, Bonsall, D, Evans, A, Golubchik, T, Gordon, AC, Lamikanra, A, Tsang, P, Ciccone, NA, Leuscher, U, Slack, W, Laing, E, Mouncey, PR, Ziyenge, S, Oliveira, M, Ploeg, R, Rowan, KM, Shankar-Hari, M, Roberts, DJ, Menon, DK, Estcourt, L, Simmonds, P, Harvala, H |
---|---|
Materialtyp: | Journal article |
Språk: | English |
Publicerad: |
Oxford University Press
2021
|
Liknande verk
Liknande verk
-
Highly sensitive lineage discrimination of SARS-CoV-2 variants through allele-specific probe PCR
av: Ratcliff, J, et al.
Publicerad: (2022) -
Interleukin-6 receptor antagonists in critically ill patients with Covid-19
av: Gordon, AC, et al.
Publicerad: (2021) -
Effects of SARS-CoV-2 strain variation on virus neutralisation titres: therapeutic use of convalescent plasma
av: Nguyen, D, et al.
Publicerad: (2021) -
Seroprevalence and virologic surveillance of Enterovirus 71 and Coxsackievirus A6, United Kingdom, 2006-2017
av: Kamau, E, et al.
Publicerad: (2021) -
Seroprevalence and Virologic Surveillance of Enterovirus 71 and Coxsackievirus A6, United Kingdom, 2006–2017
av: Everlyn Kamau, et al.
Publicerad: (2021-09-01)